AI system can equal or surpass ophthalmologists in diagnosis, treatment of glaucoma and retina disorders

A large language model (LLM) artificial intelligence (AI) system can match, or in some cases outperform, human ophthalmologists in the diagnosis and treatment of patients with glaucoma and retina disease, according to research from New York Eye and Ear Infirmary of Mount Sinai (NYEE).

How hybrid models and tech are shaping the future of clinical research – Pharmaceutical Technology

The world of clinical trials is undergoing a rapid change. Today, the rise of decentralized clinical trials (DCTs) and hybrid models has transformed the landscape,

November 5, 2024

Neurofilament Light Predicts MS Worsening in Silent Progression

Neuroaxonal pathology occurred in advance of — not coincident with — clinical worsening in multiple sclerosis (MS), particularly in patients with “silent progression” or progression

October 18, 2023

TRYP THERAPEUTICS RECEIVES CONFIRMATION FROM FDA TO PROCEED WITH PHASE 2A CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL – Biotech Investments

, 07/13/2023 / 06:00, EST/EDT – EQS Newswire – Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange,

July 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.